Carisoprodol
A centrally acting skeletal muscle relaxant prescribed for the short-term relief of acute musculoskeletal pain and discomfort. Its mechanism involves modulation of neuronal communication in the spinal cord and brain rather than a direct effect on muscle tissue. Because of its potential for dependence and abuse, it is classified as a controlled substance in many countries.
Berat Molekul
260,3300 g/mol
LogP
1,90
TPSA
90,70 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCCC(C)(COC(N)=O)COC(=O)NC(C)C
InChI
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
Molecular Formula
C12H24N2O4
HBD / HBA
2 / 4
Ikatan yang Dapat Dirotasi
9
Atom Berat
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A centrally acting skeletal muscle relaxant prescribed for the short-term relief of acute musculoskeletal pain and discomfort. Its mechanism involves modulation of neuronal communication in the spinal cord and brain rather than a direct effect on muscle tissue. Because of its potential for dependence and abuse, it is classified as a controlled substance in many countries.
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Yes, Carisoprodol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1233. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2576. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="carisoprodol"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/carisoprodol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/carisoprodol/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/carisoprodol/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="carisoprodol"></drugfyi-drug>